Integrating Multidisciplinary Care in the Diagnostic and Therapeutic Management of B-cell Non-Hodgkin Lymphomas
Presented by the Albert Einstein College of Medicine and Montefiore Medical Center in Joint Providership with PlatformQ Health Education, LLC
Release date: February 27, 2019
Valid through: August 27, 2019
This activity is supported by independent educational grants from Bayer HealthCare Pharmaceuticals Inc.; Celgene Corporation; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Estimated Time to Complete Activity: This activity consists of one session, which should take approximately 1 hour to complete.
This activity is intended for hematologists, oncologists, hematology-oncology advanced practice providers and nurses, pharmacists, and other clinicians interested/involved in the management of patients with NHL.
Upon completion of this activity, participants should be able to:
- Examine the implications of B-cell NHLs as a disease, including accurate diagnosis, risk stratification and molecular biomarkers, to aid prognosis and treatment choice
- Review the current treatment options available, treatment paradigms, and ongoing clinical trials for patients with B-cell NHLs
- Plan for a multidisciplinary approach to treatment selection, management of, and practical considerations for patients with B-cell NHL
- Apply new clinical data to effectively integrate available treatments into the standard of care for patients with B-cell NHLs
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
All other health care professionals completing this course will be issued a statement of participation.
John P. Leonard, MD
Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Associate Dean for Clinical Research
Associate Director, Sandra and Edward Meyer Cancer Center
Executive Vice Chair, Joan and Sanford I. Weill Department of Medicine
Weill Cornell Medicine
Orel Agami, PA
Staff Associate in Medicine
Weill Cornell Medical Center
Jennifer Santamala, PharmD, BCOP
Clinical Pharmacy Manager, Hematology/Oncology
Weill Cornell Medical Center
The activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine and PlatformQ Health Education, LLC. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statements
Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Academy of Nurse Practitioners (AANP) and American Nurses Credentialing Center (ANCC) accept AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
Method of Participation
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. It is estimated that this module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the posttest.
The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.
The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.
|John P. Leonard, MD||Consulting Fee: ADC Therapeutics, AstraZeneca, Bayer, BeiGene, Biotest, Celgene, Karyopharm, MEI Pharma, Merck, MorphoSys, Nordic Nanovector, Novartis, Roche/Genentech, Sandoz, Sutro|
|Orel Agami, PA||Has nothing to disclose relevant to this activity.|
|Jennifer Santamala, PharmD, BCOP||Has nothing to disclose relevant to this activity.|
|Amit Verma, MBBS||Consulting Fee: Celgene, Stelexis|
|Victor B. Hatcher, PhD||Has nothing to disclose relevant to this activity.|
|Einstein-Montefiore Center for Continuing Medical Education||The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine has no disclosures to report relevant to this activity.|
|PlatformQ Health Education, LLC||Disclosures|
|Agnes Lee, Medical Director||Has nothing to disclose relevant to this activity.|
|Alissa Yost, Senior Program Manager||Has nothing to disclose relevant to this activity.|
The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.
The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by Albert Einstein College of Medicine, OMedLive, PlatformQ Health Education, LLC or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media
Please contact the Postgraduate Institute for Medicine at www.pimed.com.
For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.
Information we collect is primarily used to communicate with program participants, award CME/CE credits, manage user accounts, recommend relevant programs and perform data analysis to inform educational outcomes.
In plain English, here is what we affirm:
- You can change your registration profile at any time from our “Profile” page
- To request any of these changes without logging in, please call us at 1 (877) 394-1306 or email us at support@PlatformQHealth.com
- You can end your association with PlatformQ Health at any time
- PlatformQ Health does not spam, nor do we do we rent or sell our email list in whole or in part. Any program-related data sharing is for engagement verification and opt-in based further education
- EU citizens can request a complete record of their account and/or request to have their personal data expunged by contacting firstname.lastname@example.org with the subject line “Data Request”